Jazz Pharmaceuticals (NASDAQ: JAZZ) SVP sells 2,238 shares on 12/09/2025

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc disclosed that senior vice president of technical operations Mary Elizabeth Henderson sold 2,238 ordinary shares on 12/09/2025. The transaction was reported with code "S" for an open-market or private sale at a weighted average price of $169.511, with individual trades executed between $169.00 and $169.82. Following these sales, she directly beneficially owns 19,508 ordinary shares of Jazz Pharmaceuticals.

Insider Trade Summary

Net Seller: 2,238 shares ($379,366)

Net Sell 1 txn

Insider Henderson Mary Elizabeth

Role SVP, Technical Operations

Sold 2,238 shs ($379K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,238	$169.511	$379K

Holdings After Transaction: Ordinary Shares — 19,508 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Mary Elizabeth

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Technical Operations

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/09/2025		S		2,238	D	$169.511(1)	19,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $169.00 to $169.82. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

	By: /s/Paz Dizon, as attorney in fact For: Mary Elizabeth Henderson	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report in this Form 4?

The company reported that officer Mary Elizabeth Henderson, senior vice president of technical operations, sold 2,238 ordinary shares of Jazz Pharmaceuticals on 12/09/2025.

At what price were the Jazz Pharmaceuticals (JAZZ) shares sold by the insider?

The sale was reported at a weighted average price of $169.511 per share, with individual trades executed at prices ranging from $169.00 to $169.82.

How many Jazz Pharmaceuticals (JAZZ) shares does the reporting person own after the sale?

After the reported transaction, Mary Elizabeth Henderson beneficially owns 19,508 ordinary shares of Jazz Pharmaceuticals, held directly.

What is the role of the reporting person at Jazz Pharmaceuticals (JAZZ)?

The reporting person, Mary Elizabeth Henderson, is an officer of Jazz Pharmaceuticals, serving as SVP, Technical Operations.

How was the insider sale by the Jazz Pharmaceuticals (JAZZ) officer executed?

The transaction was coded as "S" for sale of ordinary shares and consisted of multiple executions, with the price range and weighted average price disclosed, and share and price details available on request as stated.